Romantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.
Jeffrey V. Matous, MD
Advertisement
Articles by Jeffrey V. Matous, MD
Advertisement
Latest Updated Articles
Ramantamig's 93.6% ORR and Outpatient CRS ControlSeptember 27th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
5